Vertex Pharmaceuticals Incorporated (VRTX) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day and welcome to the Vertex Pharmaceuticals first quarter 2025 earnings call. All participants will be in a listen-only mode. Should you need assistance, please signal conference specialists by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your touchtone phone. And to withdraw your question, please press star then two. Please note this event is being recorded. I would now like to turn the conference over to Ms. Suzy Lisa. Please go ahead, ma'am. Good evening, all. My name is Suzy Lisa, and as the Senior Vice President of Investor Relations, it is my pleasure to welcome you to our first quarter 2025 Financial Results Conference Call. On tonight's call, making prepared remarks, we have Dr. Reshma Kewalramani, Vertex's CEO and President, Stuart Arbuckle, Chief Operating Officer, Charlie Wagner, Chief Financial Officer, and Duncan McKechnie, SVP, North America Commercial Operations, and come July 1, Chief Commercial Officer. We recommend that you access the webcast slides as you listen to this call. The call is being recorded and a replay will be available on our website. We will make forward-looking statements on this call that are subject to the risks and uncertainties discussed in detail in today's press release and in our filings with the Securities and Exchange Commission. These statements, including without limitation, those regarding Vertex's marketed medicines for cystic fibrosis, sickle cell disease, beta thalassemia, and moderate to severe acute pain, are pipelined and Vertex's future financial performance are based on management's current assumptions. Actual outcomes and events could differ materially. I would also note that select fina...